JPS5899471A
(ja)
*
|
1981-12-07 |
1983-06-13 |
Tanabe Seiyaku Co Ltd |
ベンゾチアゼピン誘導体の新規製造法
|
US4940704A
(en)
*
|
1989-08-16 |
1990-07-10 |
Hoechst-Roussel Pharmaceutical Inc. |
Pyrido[3,4-b][1,4]benzoxazepines
|
DK0419861T3
(da)
*
|
1989-08-29 |
1996-03-04 |
Boehringer Ingelheim Pharma |
Anvendelse af dibenz(b,f) (1,4)oxazepin (og thiazepin)-11(10H)-oner og -thioner til fremstilling af farmaceutisk præparat til forebyggelse eller behandling af AIDS
|
GB9021813D0
(en)
*
|
1990-10-08 |
1990-11-21 |
Ici Plc |
Tricyclic heterocycles
|
US5212169A
(en)
*
|
1991-10-31 |
1993-05-18 |
G. D. Searle & Co. |
Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
|
US5304644A
(en)
*
|
1992-04-15 |
1994-04-19 |
G. D. Searle & Co. |
1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
|
US5449673A
(en)
*
|
1992-08-13 |
1995-09-12 |
G. D. Searle & Co. |
10,11-dihydro-10-(3-substituted-1-oxo-2-propyl, propenyl or propynyl)dibenz[b,f][1,4] oxazepine prostaglandin antagonists
|
US5395932A
(en)
*
|
1993-04-30 |
1995-03-07 |
G. D. Searle & Co. |
2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
|
US5354746A
(en)
*
|
1993-06-01 |
1994-10-11 |
G. D. Searle & Co. |
Squaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
|
US5354747A
(en)
*
|
1993-06-16 |
1994-10-11 |
G. D. Searle & Co. |
2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
|
US5461047A
(en)
*
|
1993-06-16 |
1995-10-24 |
G. D. Searle & Co. |
2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
|
US5424424A
(en)
*
|
1993-10-07 |
1995-06-13 |
G. D. Searle & Co. |
Tartaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
|
US5420270A
(en)
*
|
1993-10-07 |
1995-05-30 |
G. D. Searle & Co. |
Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
|
US5488046A
(en)
*
|
1993-11-03 |
1996-01-30 |
G. D. Searle & Co. |
Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
|
US5441950A
(en)
*
|
1994-06-09 |
1995-08-15 |
G. D. Searle & Co. |
Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
|
US5449675A
(en)
*
|
1994-06-09 |
1995-09-12 |
G. D. Searle & Co. |
Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
|
US5698551A
(en)
*
|
1995-04-07 |
1997-12-16 |
Novo Nordisk A/S |
Heterocyclic compounds
|
AR040778A1
(es)
|
2002-08-06 |
2005-04-20 |
Glaxo Group Ltd |
Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
|
DE10242488A1
(de)
*
|
2002-09-13 |
2004-03-25 |
Bayer Ag |
Dibenzoxazeptine
|
GB0525662D0
(en)
|
2005-12-16 |
2006-01-25 |
Glaxo Group Ltd |
Immunoglobulins
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
JP2012522749A
(ja)
|
2009-04-01 |
2012-09-27 |
グラクソ グループ リミテッド |
抗il−23免疫グロブリン
|
KR20130028055A
(ko)
|
2010-01-28 |
2013-03-18 |
글락소 그룹 리미티드 |
Cd 127 결합 단백질
|
EP2534175A2
(de)
|
2010-02-09 |
2012-12-19 |
Glaxo Group Limited |
Behandlung einer stoffwechselkrankheit
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
AU2011267089B2
(en)
|
2010-06-14 |
2017-02-16 |
Lykera Biomed Sa |
S100A4 antibodies and therapeutic uses thereof
|
MY170404A
(en)
|
2010-11-23 |
2019-07-27 |
Glaxo Group Ltd |
Antigen binding proteins
|
ES2784628T3
(es)
|
2011-03-29 |
2020-09-29 |
Glaxosmithkline Llc |
Sistema de tampón para purificación de proteína
|
SG193963A1
(en)
|
2011-04-07 |
2013-11-29 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
RS64791B1
(sr)
|
2011-05-27 |
2023-11-30 |
Glaxo Group Ltd |
Bcma (cd269/tnfrsf17) - vezujući proteini
|
EP2870177A1
(de)
|
2012-07-05 |
2015-05-13 |
Glaxo Group Limited |
Optimaler dosierungsplan für einen anti-nogo-a-antikörper bei der behandlung von amyotropher lateralsklerose
|
CN104704129A
(zh)
|
2012-07-24 |
2015-06-10 |
药品循环公司 |
与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
|
PE20190845A1
(es)
|
2012-07-27 |
2019-06-17 |
Aragon Pharmaceuticals Inc |
Metodos para determinar resistencia a terapia de receptor de androgeno
|
AU2014230741B2
(en)
|
2013-03-15 |
2017-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
CN105188872B
(zh)
|
2013-03-15 |
2019-01-15 |
葛兰素史克知识产权第二有限公司 |
用于纯化抗体的方法
|
ES2665596T3
(es)
|
2013-03-15 |
2018-04-26 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Uso de compuestos intermedios de ácido tricarboxílico (ATC) para controlar la generación de amoníaco en cultivo celular
|
WO2014141149A1
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations with reduced viscosity
|
SG11201506499YA
(en)
|
2013-03-15 |
2015-09-29 |
Glaxosmithkline Ip No 2 Ltd |
Low concentration antibody formulations
|
TWI694836B
(zh)
|
2014-05-16 |
2020-06-01 |
英商葛蘭素史克智慧財產管理有限公司 |
抗體調配物
|
CA2953807A1
(en)
|
2014-06-26 |
2015-12-30 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
WO2017021911A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
EP3331917A1
(de)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlungen sowie verwendungen und verfahren davon
|
RU2018107693A
(ru)
|
2015-08-04 |
2019-09-05 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Комбинированные виды лечения и их варианты применения и способы
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
CA2994790A1
(en)
|
2015-08-06 |
2017-02-09 |
Christopher W. Cluff |
Tlr4 agonists and compositions thereof and their use in the treatment of cancer
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
EP3331919A1
(de)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapie mit anti-ctla-4-antikörpern
|
KR20180042412A
(ko)
|
2015-09-02 |
2018-04-25 |
이뮤텝 에스.에이.에스. |
항-lag-3 항체
|
EP4015537A1
(de)
|
2015-12-01 |
2022-06-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlungen und verwendungen und verfahren dafür
|
EP3494140A1
(de)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos- und anti-pd-1-antikörper-kombinationstherapie
|
GB201614627D0
(en)
|
2016-08-30 |
2016-10-12 |
Glaxosmithkline Ip Dev Ltd |
Antigen binding proteins
|
WO2018047080A1
(en)
|
2016-09-07 |
2018-03-15 |
Glaxosmithkline Intellectual Property Development Limited |
Methods for purifying antibodies
|
AU2017369994A1
(en)
|
2016-12-01 |
2019-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
KR20190090822A
(ko)
|
2016-12-01 |
2019-08-02 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
조합 요법
|
EP3582855A1
(de)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapie zur behandlung von krebs
|
EP3635011A1
(de)
|
2017-06-09 |
2020-04-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationstherapie mit icos-agonist und ox40-agonisten zur behandlung von krebs
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
JP2020522556A
(ja)
|
2017-06-09 |
2020-07-30 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
癌を治療するためのicosアゴニストおよびox40アゴニストでの組み合わせ療法
|
BR112020005028A2
(pt)
|
2017-09-14 |
2020-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
tratamento em combinação para câncer
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
TW202003555A
(zh)
|
2018-03-07 |
2020-01-16 |
英商葛蘭素史克智慧財產發展有限公司 |
用於純化重組多肽之方法
|
TW202000891A
(zh)
|
2018-03-07 |
2020-01-01 |
英商葛蘭素史克智慧財產發展有限公司 |
純化抗體之方法
|
BR112020023451A2
(pt)
|
2018-05-31 |
2021-02-23 |
Glaxosmithkline Intellectual Property Development Limited |
terapia combinada
|
EP3801615A1
(de)
|
2018-05-31 |
2021-04-14 |
GlaxoSmithKline Intellectual Property Development Ltd |
Kombinierte therapie mit icos-bindenden proteinen und arginin-methyltransferase-hemmern
|
WO2020031087A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
JP2022513374A
(ja)
|
2018-10-22 |
2022-02-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
投薬
|
AU2020214412A1
(en)
|
2019-02-01 |
2021-08-12 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
CN114222760A
(zh)
|
2019-06-26 |
2022-03-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
Il1rap结合蛋白
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
WO2021046289A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021152495A1
(en)
|
2020-01-28 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
GB202004371D0
(en)
|
2020-03-26 |
2020-05-13 |
Glaxosmithkline Ip Dev Ltd |
CAR constructs
|
AU2021257570A1
(en)
|
2020-04-14 |
2022-11-03 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
EP4136105A1
(de)
|
2020-04-14 |
2023-02-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlung für krebs auf basis eines icos-antikörpers und eines pd-l1-antikörper-tgf-beta-rezeptor-fusionsproteins
|
AU2021256652A1
(en)
|
2020-04-14 |
2022-11-03 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
|
TWI821804B
(zh)
|
2020-12-02 |
2023-11-11 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
Il-7結合蛋白及其於醫療中之用途
|
KR20230160307A
(ko)
|
2021-03-19 |
2023-11-23 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
클라우딘-3을 표적화하는 키메라 항원 수용체 및 암을 치료하는 방법
|
WO2023041985A2
(en)
|
2021-09-15 |
2023-03-23 |
New York University In Abu Dhabicorporation |
Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
|
WO2023227641A1
(en)
|
2022-05-27 |
2023-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment
|